OpGen

OpGen, Inc. is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It engages in the development of molecular information products and services for global healthcare settings. The firm's also offers guidance to clinicians about life threatening infections, improving patient outcomes, and decreasing the spread of infections caused by multidrug-resistant microorganisms. Its products include Unyvero, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction. The company was founded on January 22, 2001 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Strategic partnership will focus on commercializing CELLSEARCH platform for COVID-19 related use cases, along with other COVID-19 related products Strategic partnership will focus on commercializing CELLSEARCH platform for COVID-19 related use cases, along with other COVID-19 related products

Menarini Silicon Biosystems Partners with OpGen to Broaden Distribution of CELLSEARCH Platform in North America

-  European Investment Bank (EIB) and OpGen, Curetis GmbH and Ares Genetics GmbH enter into Amendment to the EIB Financing Agreement

OpGen Subsidiary Curetis GmbH Secures Access to Additional EUR 5.0 Million Non-Dilutive Debt Financing Tranche from EIB

Agenus

Amyris

Inspired Entertainment

RTI Surgical

If you’re looking for some hedges for your portfolio or are looking to shift against the market, our deep learning algorithms and AI technology have several Top Shorts for you today.

Top Stocks To Short During Current Market Sell Off

OpGen (NASDAQ: OPGN) shares are trading higher after the company announced its Unyvero HPN Panel identifies bacterial co-infections in hospitalized patients with COVID-19 pneumonia in just five hours.

Why OpGen Shares Are Trading Higher Today

GAITHERSBURG, Md. and HOLZGERLINGEN, Germany, June  09, 2020  (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced today preliminary data from an investigator initiated collaboration with Karolinska Institutet, Stockholm, Sweden, to identify bacterial co-infections in hospitalized patients with COVID-19 pneumonia. The patients in this cohort had been admitted to the ICU after respiratory deterioration during hospital stay, and their lower respiratory tract samples were analyzed with the Unyvero HPN panel.

OpGen Releases Preliminary Data Demonstrating its Unyvero HPN Panel for Pneumonia Identifies Life-Threatening Bacterial Co-Infections in COVID-19 Patients in Just Five Hours

GAITHERSBURG, Md., May  11, 2020  (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, to issued two letters to stockholders from new OpGen CEO Oliver Schacht and Chairman of the Board William Rhodes. Both letters can be found in full below:

OpGen CEO and Chairman of the Board Issue Letters to Stockholders

OpGen, Inc. (OPGN) CEO Oliver Schacht on Q1 2020 Results - Earnings Call Transcript

- Investigator initiated study at Sweden’s Karolinska Institutet to test COVID-19 pneumonia patients with Unyvero HPN panel for bacterial co-infections

OpGen Subsidiary Curetis GmbH and Karolinska Institutet Collaborate in Study of Bacterial Co-Infections in COVID-19 Pneumonia Patients

Peer-reviewed study evaluated performance of AI-powered bioinformatics cloud platform, ares-genetics.cloud, for NGS-based antibiotic susceptibility testing on 12 pathogenic bacterial species and 21 antibiotic drugs

OpGen Subsidiary Ares Genetics Demonstrates Feasibility and Potential of Next Generation Sequencing Based Antibiotic Susceptibility Testing in Multi-Center Study

Following strong support from shareholders, OpGen and Curetis consummated their business combination transaction

OpGen and Curetis Successfully Close their Business Combination Transaction

Vote approving transaction passes with 95% support for the transaction

OpGen Announces Shareholder Approval for Business Combination with Curetis

OpGen, Inc. (OPGN) CEO Evan Jones on Q4 2019 Results - Earnings Call Transcript

Shareholder proxy vote achieves quorum with 99% support for the transaction

OpGen Provides Further Update on Shareholder Proxy Voting in Relation to the Business Combination with Curetis

In an analysis of K. pneumoniae bacterial isolates, an overall agreement of 95.6% was observed between phenotypic antimicrobial susceptibility and genotypic prediction by OpGen’s Acuitas Lighthouse® platform using whole genome sequencing data In an analysis of K. pneumoniae bacterial isolates, an overall agreement of 95.6% was observed between phenotypic antimicrobial susceptibility and genotypic prediction by OpGen’s Acuitas Lighthouse® platform using whole genome sequencing data

OpGen Data Predicting Phenotypic Antimicrobial Susceptibility Published in Diagnostic Microbiology & Infectious Disease Journal

Shareholder proxy vote stands at 97% of the required quorum with support for the transaction at over 95% Shareholder proxy vote stands at 97% of the required quorum with support for the transaction at over 95%

OpGen Provides Update on Shareholder Proxy Voting in Relation to the Business Combination with Curetis

OpGen (OPGN) news for Monday includes OPGN stock taking off following an update on test kits for the coronavirus from China.
The post OpGen (OPGN) Stock Skyrockets 128% on Rapid Coronavirus Test Kit News appeared first on InvestorPlace.

OpGen (OPGN) Stock Skyrockets 128% on Rapid Coronavirus Test Kit News

OpGen Inc (NASDAQ: OPGN) shares were ripping higher Monday in reaction to an announcement regarding a COVID-19 test kit from German molecular diagnostics company Curetis, which OpGen has agreed to merge with.

Nano-Cap OpGen Skyrockets On COVID-19 Connection

- Rapid real-time PCR test allows testing for SARS-CoV2 in only a few hours

OpGen Provides Update on Curetis Now Offering BGI’s CE-IVD Rapid Test Kit for Coronavirus in Europe

Revenue increases by 64% to EUR 2.3 million, up from 1.4 million in 2018

OpGen Provides Update on Curetis Preliminary, Unaudited 2019 Condensed Combined Key Financials and Business Update

GAITHERSBURG, Md., Feb.  12, 2020  (GLOBE NEWSWIRE) --  OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that total revenue for 2019 increased 18.7% to $3.5 million, up from $3.0 million in 2018. The company also announced accomplishment of the following key milestones:

OpGen Announces Preliminary Unaudited Revenue for Fiscal 2019 and Provides Business Update

OpGen Inc. (NASDAQ: OPGN) shares jumped on Thursday after the company announced that it will be joining the fight against the coronavirus (2019-nCov).

OpGen Takes a Different Approach to the Coronavirus

GAITHERSBURG, Md., Jan.  30, 2020  (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) reported an update on the business of Curetis GmbH (“Curetis”), the other party to the planned business combination with OpGen. Today, Curetis announced that Ares Genetics GmbH, a Curetis Group company, and the Chinese genomics company BGI Group will collaborate in making molecular testing for the new coronavirus 2019-nCoV available in Europe.

OpGen Provides Update on Curetis Group Company Ares Genetics’ Collaboration with BGI Group to Offer Next-Generation Sequencing and PCR-based Coronavirus (2019-nCoV) Testing in Europe

GAITHERSBURG, MD, Jan.  28, 2020  (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that a key milestone has been accomplished in the proposed business combination with Curetis, N.V. (Euronext: CURE, “Curetis”), a developer of next-level molecular diagnostic solutions. On January 27, 2020, OpGen filed and furnished to its stockholders a proxy statement/prospectus and a notice of special meeting of OpGen stockholders, to be held on March 10, 2020 at 10:00am ET at the offices of Ballard Spahr LLP, 1909 K Street, NW, 12 th  Floor, Washington DC.  At the special meeting, OpGen is seeking shareholder approval of the business combination of OpGen and Curetis. Curetis will host its shareholder meeting on the same day at 1:00pm CET with the same objective. The Curetis extraordinary general meeting will take place at Steigenberger Hotel, Stationsplein Zuid - West 951, 1117 CE Schiphol - Oost/Amsterdam, the Netherlands. Successful votes of the shareholders of the respective companies are the last remaining major steps towards closing of the transaction.

OpGen Achieves Key Milestone in Planned Business Combination with Curetis

- Broad Unyvero LRT BAL panel also includes atypical pathogens such as Pneumocystis jirovecii

News for OpGen Stock (OPGN)